Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103699 · ClinicalTrials.gov registry record
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
A clinical trial, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 315
- Enrollment target
NCT02103699: Completed study, sponsored by Janssen Scientific Affairs.
NCT02103699 is a clinical trial that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 315 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02103699 has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 315 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of a simeprevir-containing hepatitis C virus (HCV) treatment regimen as measured by sustained virologic response (SVR).
Primary Outcome
SVR is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) undetectable at least 12 weeks after the actual end of all HCV treatment. Actual end of treatment will be determined by health care provider.
Interventions
- DRUG No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-01 |
What the finished NCT02103699 record still lists
NCT02103699 is an observational study that tracks outcomes without assigning an intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT02103699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02103699 about?
NCT02103699 is a clinical study titled "A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir". The purpose of this study is to evaluate the effectiveness of a simeprevir-containing hepatitis C virus (HCV) treatment regimen as measured by sustained virologic response (SVR).
What is the current status of trial NCT02103699?
This trial is currently completed. The enrollment target is 315 participants. The study started on 2014-02. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02103699?
The interventions under investigation include: No intervention (DRUG).
Who is sponsoring clinical trial NCT02103699?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia